ELOXX PHARMACEUTICALS, INC. Business Combination, Acquisition Related Costs
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Business Combination, Acquisition Related Costs of $761.00 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-08-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2018-08-10
- ELOXX PHARMACEUTICALS, INC. business combination, acquisition related costs for the quarter ending 2018-03-31 was $761.00K.
- ELOXX PHARMACEUTICALS, INC. business combination, acquisition related costs for fiscal 2016 was $0.00.
- ELOXX PHARMACEUTICALS, INC. business combination, acquisition related costs for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- ELOXX PHARMACEUTICALS, INC. business combination, acquisition related costs for fiscal 2014 was $544.98K.
- ELOXX PHARMACEUTICALS, INC. business combination, acquisition related costs for fiscal 2013 was $0.00.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 3 month as first filed | Business Combination, Acquisition Related Costs 12 month |
|---|---|---|---|
| 2018-03-31 | $761.00K 10-Q · filed 2018-08-10 | $2.06M 10-Q · filed 2018-05-10 | |
| 2016-06-30 | $0.00 10-K · filed 2016-10-13 | ||
| 2015-06-30 | $0.00 10-K · filed 2016-10-13 | ||
| 2014-06-30 | $544.98K 10-K · filed 2016-10-13 | ||
| 2013-06-30 | $0.00 10-K · filed 2015-10-09 | ||
| 2012-06-30 | $0.00 10-K · filed 2014-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |